15 - 17 October, 2012
The Ritz Carlton, Laguna Niguel, CA

Conference Day One

We are currently developing the program for BioNetwork West 2012. As a courtesy, we're providing our most recent BioNetwork West Agenda.

Request an outline for the 2012 Agenda! Email us at bionetwork@wbresearch.com

7:30 Networking Breakfast & Conference Registration Sponsored By Sanofi
Networking Breakfast & Conference Registration Sponsored By Sanofi
8:45 Chairperson's Opening Remarks
Jeff Totten, Vice President Life Sciences Practice, Dean & Company
Chairperson's Opening Remarks
10840_005_jeff totten - new photo

Jeff Totten
Vice President Life Sciences Practice, Dean & Company

Mr. Totten is a Vice President of Dean & Company and head of its Life Sciences practice. Prior to joining the firm, Mr. Totten was a Principal at Mercer Management Consulting (now Oliver Wyman), and one of the founders of its Life Sciences practice. Previously, Mr. Totten worked in Brand Management at the Procter & Gamble Company.Mr. Totten’s work has spanned corpor [read more]
9:00 Panel: Trends In Pharma M&A Activity
Erin Lavelle, Executive Director, Amgen Strategy and Corporate Development, Amgen Incorperation
Ellen Lubman, Group Director, Strategic Transactions Group, Bristol-Myers Squibb Company
Richard Masterson, Jr., President & COO, Valeant International (Barbados) SRL
Jon Norris, Managing Director, SVB Capital
Matt Porzio, VP of Product Marketing , Intralinks
Pharma continued to witness major M&A deals in 2010. And as the struggle to protect revenue loss against upcoming patent expirations continues, conditions are prime for the pace of M&A to increase in 2011. Emerging markets and new distribution channels are the focal points of many M&A strategies. This session will cover the drivers for the various M&A strategies, projections for competitive pricing and creative acquisitive deal structures like the contingent value rights (CVR) structure.
10386.006_bioNetworkWest_2011_erin_lavelle

Erin Lavelle
Executive Director, Amgen Strategy and Corporate Development, Amgen Incorperation

10386.006_bioNetworkWest_2011_ellen_lubman_bionetwork_photo

Ellen Lubman
Group Director, Strategic Transactions Group, Bristol-Myers Squibb Company

Ellen Lubman is a Group Director in the Strategy, Alliances and Transactions Group at Bristol-Myers Squibb. Ellen focuses on M&A execution and strategy, identification of new transaction opportunities, and initiation of “String of Pearls transactions, as well as spearheading novel business initiatives. Prior to joining Bristol-Myers Squibb, Ellen worked with Celtic Pharma, L.P., a [read more]
10386.006_bioNetworkWest_2011_rich_masterson_head_shot_1

Richard Masterson, Jr.
President & COO, Valeant International (Barbados) SRL

Rich Masterson is President of Valeant International (Barbados) SRL and Chariman of its Board. He leads Valeant’s wholly owned subsidiary in Barbados, which is the locus of the majority of the asset purchase transactions completed by the Company. He has more than twenty-two years of experience in the pharmaceutical industry spanning a broad range of commercial responsibilities in numerous therapeu [read more]
10386.006_bioNetworkWest_2011_jon_norris_1

Jon Norris
Managing Director, SVB Capital

Jon Norris is a managing director with SVB Capital's Venture Capital Relationship Management team, specializing in life sciences. Norris oversees strategic relationships with select life science venture capital firms on the West Coast, sourcing and advising on direct equity co-investment, limited partnership, and portfolio company banking and lending opportunities. In addition, he helps life scien [read more]
10386_006_Matt_Porzio.jpg

Matt Porzio
VP of Product Marketing , Intralinks

Matthew Porzio, Vice President of Product Marketing, joined IntraLinks in August of 2003. He is responsible for driving the development and marketing of IntraLinks' Exchanges including virtual dealroom/dataroom solutions for the M&A and restructuring communities. Before joining IntraLinks, he was a senior associate at Metzler, a German advisory firm, where he focused on cross-borde [read more]
10:00 Panel: Timing The Deal – Finding The Balance Between Risk And Reward
Milton Grannatt, VP & Head, Negotiations, Respiratory & New Growth Opportunities, Novartis Pharmaceuticals Corporation
Jonathan Mow, VP of Business Development, Amylin
Guy Van Meter, Senior Director, Head of Business Development, adimab
Ben Bonifant, Senior Vice President and Practice Area Leader, Campbell Alliance
All licensors in the biopharma industry share the challenge of timing the deal to balance the risk and financial reward. In this session,we'll hear from both in-licensors and out-licensors sharing their personal experiences of making decisions on timing the deal. The panelists will discuss trends in pharma licensing from the last year, identify market indicators for when a deal may occur and how to prepare for influencers beyond your control.
Milton Grannatt

Milton Grannatt
VP & Head, Negotiations, Respiratory & New Growth Opportunities, Novartis Pharmaceuticals Corporation

Milt Grannatt is Vice President and Head, Negotiations for Respiratory in Global Business Development and Licensing at Novartis. Prior to Novartis, he held senior positions at Sterling Winthrop and Lex Service, an acquisitive UK-based company. Dr. Grannatt has an extensive deal sheet.
10386.006_bioNetworkWest_2011_jonathan_mow_07

Jonathan Mow
VP of Business Development, Amylin

Jonathan Mow is Vice President, Business Development for Amylin Pharmaceuticals located in San Diego, CA since he joined the company in 2007. Prior to joining Amylin, Mr. Mow was Co-founder, Vice President, Commercial and Business Development, and Secretary of Corus Pharma, Inc. until their acquisition by Gilead Sciences in 2006. From 1997 to 2000, Mr. Mow led the Business Development efforts for [read more]
10386_006_Guy_VanMeter.jpg

Guy Van Meter
Senior Director, Head of Business Development, adimab

Guy Van Meter is Head of Business Development for Adimab, LLC, an antibody discovery company. In the first 2 years from platform launch, Mr. Van Meter has helped build Adimab into one of the most successful antibody platform companies in the industry, generating deals with Merck, Roche, Pfizer, Lilly, Novartis, Genentech, Novo Nordisk, BiogenIdec and other top pharma companies. Prior to Adimab, Mr [read more]
10386.006_bioNetworkWest_2011_ben_bonifant_campbell_alliance

Ben Bonifant
Senior Vice President and Practice Area Leader, Campbell Alliance

Ben Bonifant is the leader of Campbell Alliance’s Business Development practice. In that role, Mr. Bonifant assists leaders in large and small pharmaceutical and biotechnology companies on key licensing and acquisition initiatives. He also acts as a strategic advisor to venture capital and private equity decision makers. Prior to joining Campbell, Mr. Bonifant was a partner in the Strategy Practic [read more]
11:00 Refreshment Break & Networking Opportunity Hosted By: Sanofi
Refreshment Break & Networking Opportunity
11:30 Panel: Innovative Deal Structures For 2012 And Beyond
Brent Bankosky, Vice President Business Development, Tranzyme Pharma
David Donabedian, VP Global New Deal Strategy & Development, ceedd, GSK
Wael Fayad, VP Business Development, Forest Laboratories, Inc.
Baruch Harris, VP, Strategy and Operations, Enlight Biosciences
Jonathan MacQuitty, Ph.D., Partner, Abingworth Management Inc.
Risk management of deals is by no means a new concept in pharmaceutical dealmaking. Option based deals and structured acquisitions have become standard deal making tools. But what can we learn from other industries using creative deal structures? This session will take a look outside the biopharma industry for examples of deal structures and will also explore where the biopharma industry is heading with innovative deal models.
10386_006_Brent_Bankosky_2.jpg

Brent Bankosky
Vice President Business Development, Tranzyme Pharma

Mr. Bankosky joined Tranzyme Pharma as Vice President, Business Development in August, 2011. Previously, Mr. Bankosky was employed by Takeda Pharmaceuticals International, Inc. as Senior Director, Global Licensing & Business Development where he was responsible for in-licensing and out-licensing of key programs across several therapeutic areas including Diabetes, Obesity, Cardiovas [read more]
David Donabedian

David Donabedian
VP Global New Deal Strategy & Development, ceedd, GSK

Dr. Donabedian is Vice President, Global New Deal Strategy and Development and is a member of the ceedd leadership team. In this role, he is accountable for setting the ceedd new deal portfolio strategy and composition and working closely with GSK worldwide business development to establish new alliances. Prior to this position, Dr. Donabedian was the Vice President of Strategic Alliances in GSK's [read more]
Wael Fayad

Wael Fayad
VP Business Development, Forest Laboratories, Inc.

Wael has more than 17 years of experience in the pharmaceutical industry where he held positions of increasing responsibility in sales, marketing, new product development and business development. Wael joined Forest in 2001 and he currently heads the Business Development group responsible for all licensing and M&A activity. Prior to Forest, Wael worked at Schering Plough in Kenilwo [read more]
10840_005_baruch harris

Baruch Harris
VP, Strategy and Operations, Enlight Biosciences

Enlight Biosciences is a Boston-based venture creation firm, established in partnership with major pharmaceutical companies to develop breakthrough innovations that will fundamentally alter drug discovery and development. Dr. Harris manages Enlight’s day-to-day operations and is responsible for providing management support to Enlight’s portfolio companies. Prior to joining Enlight, Dr. Harris was [read more]
10386.006_bioNetworkWest_2011_jonathan_macquitty_head_shot

Jonathan MacQuitty, Ph.D.
Partner, Abingworth Management Inc.

Dr. MacQuitty has headed up Abingworth’s West Coast office since 1999. Abingworth is a leading life science investor in both US and Europe having invested in over 100 companies with over $1.3B currently being managed. Before Abingworth, Dr. MacQuitty was CEO for 9 years of GenPharm International, a biotech firm he co-founded in 1988 to develop transgenic animal technology. Prior to GenPharm, he he [read more]
12:30 Case Study: Forest Laboratories Acquires Clinical Data Inc.
Wael Fayad, VP Business Development, Forest Laboratories, Inc.
Drew Fromkin, Former CEO Clinical Data , Clinical Data (Acquired By Forest Laboratories, Inc.)
Case Study: Forest Laboratories Acquires Clinical Data Inc.
Wael Fayad

Wael Fayad
VP Business Development, Forest Laboratories, Inc.

Wael has more than 17 years of experience in the pharmaceutical industry where he held positions of increasing responsibility in sales, marketing, new product development and business development. Wael joined Forest in 2001 and he currently heads the Business Development group responsible for all licensing and M&A activity. Prior to Forest, Wael worked at Schering Plough in Kenilwo [read more]
10386_006_Drew_Fromkin.jpg

Drew Fromkin
Former CEO Clinical Data , Clinical Data (Acquired By Forest Laboratories, Inc.)

Andrew J. Fromkin joined Clinical Data, Inc. on October 12, 2005 and was elected President, Chief Executive Officer, and Executive Director on May 12, 2006. Clinical Data, Inc. (CLDA) was rapidly transformed into a public pharmaceutical company developing first-in-class and best-in-category therapeutics, with a focus on advancing late-stage products and developing related companion diagnostics. On [read more]
1:00 Networking Lunch For All Conference Attendees Hosted By Sanofi
Networking Lunch For All Conference Attendees Hosted By Sanofi
2:15 Panel: Partnering A Platform Technology Today When Companies Want A Drug Tomorrow
Hemmie Chang, Chair, Licensing & Strategic Alliances Practice Group, Foley Hoag
Phil Gutry, Principal, MPM Capital
George Golumbeski, Senior Vice President Business Development, Celgene Corporation
Kevin Skol, Director, Business Development, Isis Pharmaceuticals, Inc.
In the current economic climate, platform deals have been taking a back seat to drug development. What are the factors a company considers in building a strategy around a technology platform in comparison to creating a product strategy? This session will discuss how to gain interest from partners and structure the deal.
10386_006_Hemmie_Chang.jpg

Hemmie Chang
Chair, Licensing & Strategic Alliances Practice Group, Foley Hoag

Ms. Hemmie Chang, Partner Foley Hoag LLP. Hemmie chairs Foley Hoag’s Licensing & Strategic Alliances Group where she focuses on complex collaboration and licensing transactions. She has over two decades of experience advising both pharmaceutical and emerging biotech companies, recently advising Translational Therapeutics in a BioWorld International Deal of the Week with Clavis Phar [read more]
PGutryRevised

Phil Gutry
Principal, MPM Capital

Phil Gutry joined MPM's San Francisco office as a Principal in 2011. He previously worked for five years in Corporate Development at Gilead Sciences where he focused on M&A and licensing in antiviral, respiratory, and liver disease. His deal experience includes Gilead's acquisition of Arresto Biosciences and partnership with MicroDose Therapeutx. Prior to Gilead, Phil was a Princip [read more]
George Golumbeski

George Golumbeski
Senior Vice President Business Development, Celgene Corporation

In a career spanning nearly 20 years, George has held senior positions in R&D and Business Development. In his most recent two positions, he has led business development functions at leading oncology companies. He has a strong record of closing significant in-licensing and M&A transactions. George is currently Senior Vice President of Business Development for Celgen [read more]
Kevin Skol

Kevin Skol
Director, Business Development, Isis Pharmaceuticals, Inc.

Kevin Skol leads the business development activities at Isis Pharmaceuticals as the Director of Business Development. Kevin is primarily responsible for implementing Isis’ innovative partnering structures including its Preferred Partner Alliance model and Satellite Company strategy which now includes over a dozen technology and drug development collaborations. Prior to Isis, Kevin was a marketing [read more]
3:15 Panel: Diversifying Portfolios Outside Traditional Drug Development
Roger Graben, SVP, Operations & Business Development, Kowa Pharmaceuticals America, Inc.
James Hattersley, Vice President, Business Development, Sun Pharmaceuticals Industries Inc
Brad Prosek, Senior Director of Corporate Development, Cubist Pharmaceuticals, Inc.
Financial markets are giving higher valuations to more diversified companies. Many of the large pharmaceutical companies are diversifying away from patented drug development. In this session, we will discuss the variations in the strategies companies are taking to diversify including the shift into generics, consumer health and vaccines.
Roger Graben

Roger Graben
SVP, Operations & Business Development, Kowa Pharmaceuticals America, Inc.

Roger D. Graben, Ph.D., R.Ph. is Senior Vice President, Operations & Business Development, at Kowa Pharmaceuticals America (KPA) in Montgomery, AL. Dr. Graben is responsible for Business Development, Alliance Management, Quality Assurance, Pharmacovigilance, Regulatory Affairs, Trade, Distribution, Operations, Facilities, Fleet, and IT. Dr. Graben joined KPA in 2006 and has previou [read more]
10386.006_bioNetworkWest_2011_james_hattersley_sun

James Hattersley
Vice President, Business Development, Sun Pharmaceuticals Industries Inc

James Hattersley has over 22 years of successful leadership experience within biotechnology and pharmaceutical industries. From 1986 through 1995 Jim was responsible for R&D advancements in drug delivery at Alza Corp and Abbott Labs. From 1995 to present day 2011 Jim has led the execution of growth strategy at Sun Pharmaceutical Industries, in addition to several transactions of si [read more]
10386_006_Brad_Prosek.jpg

Brad Prosek
Senior Director of Corporate Development, Cubist Pharmaceuticals, Inc.

Brad Prosek currently serves as Senior Director, Corporate Development for Cubist Pharmaceuticals, Inc. In this role, Brad sources and structures transactions supporting Cubist’s pipeline buildout. Previously at Cubist, Brad started and led the Market Access group, a sales organization focused on developing non-hospital markets for the company’s flagship product CUBICIN (daptomycin for injection). [read more]
4:15 Refreshment Break & Networking Opportunity
Refreshment Break & Networking Opportunity
4:45 Bristol-Myers Squibb Completes Acquisition of Amira Pharmaceuticals
Hari Kumar, Ph.D., Chief Executive Officer, Panmira Pharmaceuticals
Ellen Lubman, Group Director, Strategic Transactions Group, Bristol-Myers Squibb Company
Hot transaction….fresh off the presses.Big pharma. Small biotech. Strategic fit. Innovative structure. 6 weeks from first communication to announcement of acquisition. Wouldn't it be great if all big pharma M&A could be this way?Come hear the story of Bristol Myers Squibb's acquisition of Amira Pharmaceuticals, which was announced on July 21 after a fist diligence discussion in early June. The acquisition's completion was just announced on September 8.
10840_005_hari kumar

Hari Kumar, Ph.D.
Chief Executive Officer, Panmira Pharmaceuticals

Hari Kumar brings to Panmira almost 20 years of big pharmaceutical experience. Hari spent a total of 17 years at Hoffmann-La Roche, where he began his career in basic research, moved to sales and marketing, lifecycle management, and finally, business development. In 1996, Hari moved to Eisai Ltd, where he served as the company’s European Marketing Director before returning to Roche in 1999.During [read more]
10386.006_bioNetworkWest_2011_ellen_lubman_bionetwork_photo

Ellen Lubman
Group Director, Strategic Transactions Group, Bristol-Myers Squibb Company

Ellen Lubman is a Group Director in the Strategy, Alliances and Transactions Group at Bristol-Myers Squibb. Ellen focuses on M&A execution and strategy, identification of new transaction opportunities, and initiation of “String of Pearls transactions, as well as spearheading novel business initiatives. Prior to joining Bristol-Myers Squibb, Ellen worked with Celtic Pharma, L.P., a [read more]
5:30 Cocktail Reception For All Attendees
Cocktail Reception For All Attendees
Theme2 Master Page Theme2 PageName:agenda.aspx EventInfo Id = 138050 Content Id = 138082 Content Title = dayone